Welcome to our dedicated page for American Vanguard SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Vanguard Corporation's SEC filings document the formal disclosures of a NYSE-listed specialty agriculture products company and its AMVAC Chemical Corporation operating subsidiary. Recent Form 8-K reports cover operating results, earnings-call materials, Regulation FD disclosures and material credit arrangements, including term-loan and revolving-credit amendments tied to the company's capital structure and working-capital needs.
Proxy and annual-meeting filings address board elections, director composition, auditor ratification, executive compensation and shareholder voting matters. The filings also identify the company's common stock, par value, exchange listing and governance actions related to board size and committee-level oversight.
American Vanguard Corp officer David T. Johnson received a grant of options to buy 20,000 shares of common stock. The options have an exercise price of $2.51 per share and were awarded as an incentive stock option grant.
The options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary. Following this award, Johnson holds options for 20,000 underlying common shares directly.
AMERICAN VANGUARD CORP director and CEO Douglas Kaye received a grant of 50,000 stock options. These options allow the purchase of 50,000 shares of Common Stock at an exercise price of $2.51 per share. The award is compensation-related, not an open-market trade.
The incentive stock options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary. After this grant, Kaye holds 50,000 options directly, giving potential future equity exposure if the options vest and are exercised.
American Vanguard Corporation reported the results of its 2026 annual stockholder meeting and approved special executive bonuses. Seven director nominees were elected, Deloitte Touche LLP was ratified as independent auditor for the year ending December 31, 2026, and stockholders backed annual advisory votes on pay and approved the company’s executive compensation program. The board also granted success bonuses tied to a full restructuring of the company’s borrowed debt: $150,000 to Douglas Kaye, $125,000 each to David Johnson and Timothy Donnelly, and $50,000 to Shirin Khosravi.
American Vanguard Corp’s chief executive officer, Douglas Kaye, bought additional company stock in the open market. On this transaction, the CEO purchased 5,000 shares of Common Stock at a price of $2.50 per share. After the purchase, his directly owned stake increased to 300,251 shares.
McDougal Rubin J reported acquisition or exercise transactions in this Form 4 filing.
AMERICAN VANGUARD CORP director Rubin J. McDougal received 31,872 deferred stock units (DSUs) as compensation. The award was granted in connection with the company’s 2026 annual stockholders’ meeting and is recorded at no cash cost per unit.
Each DSU represents the right to receive one share of common stock when the award settles. Settlement occurs at the earlier of the director leaving the board, a change of control, or the director’s death. Until then, the DSUs are nontransferable and carry no voting or dividend rights.
AMERICAN VANGUARD CORP director Rubin J. McDougal has filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director but shows no reported transactions, meaning it simply establishes his status as an insider without disclosing any recent trades.
American Vanguard Corp’s Chief Commercial Officer, Michael Joseph DiPaola, received an incentive stock option grant. The award covers 20,000 options to buy common stock at an exercise price of $2.51 per share.
The options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary, June 4, 2036, if not exercised. This is a compensation-related equity grant rather than an open-market share purchase or sale.
AMERICAN VANGUARD CORP director Patrick E. Gottschalk received a grant of 31,872 deferred stock units. These DSUs were awarded as part of the compensation program for non-management directors in connection with the 2026 annual stockholders' meeting, at no cash cost per unit. Following the award, Gottschalk holds 223,577 shares or units of common stock-related interests directly. Each DSU converts into one share of common stock upon settlement, which occurs when his board service ends, upon a change of control, or upon his death.
American Vanguard Corp senior vice president Jared Straley received a grant of options to buy 20,000 shares of common stock. The incentive stock options have an exercise price of $2.51 per share, vest in full on the third anniversary of the June 4, 2026 grant, and expire on June 4, 2036.